323 related articles for article (PubMed ID: 14707572)
1. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.
Shorr AF; Susla GM; Kollef MH
Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
3. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
[TBL] [Abstract][Full Text] [Related]
5. Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units.
van Nieuwenhoven CA; Buskens E; Bergmans DC; van Tiel FH; Ramsay G; Bonten MJ
Crit Care Med; 2004 Jan; 32(1):126-30. PubMed ID: 14707570
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
Bounthavong M; Hsu DI; Okamoto MP
Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain.
Grau S; Alvarez-Lerma F; del Castillo A; Neipp R; Rubio-Terrés C
J Chemother; 2005 Apr; 17(2):203-11. PubMed ID: 15920907
[TBL] [Abstract][Full Text] [Related]
8. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.
Warren DK; Shukla SJ; Olsen MA; Kollef MH; Hollenbeak CS; Cox MJ; Cohen MM; Fraser VJ
Crit Care Med; 2003 May; 31(5):1312-7. PubMed ID: 12771596
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstein R
Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
12. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
Collins CD; Schwemm AK
Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
Machado AR; Arns Cda C; Follador W; Guerra A
Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis.
Chan JD; Pham TN; Wong J; Hessel M; Cuschieri J; Neff M; Dellit TH
J Intensive Care Med; 2011; 26(6):385-91. PubMed ID: 21606058
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia.
Shorr AF; Tabak YP; Gupta V; Johannes RS; Liu LZ; Kollef MH
Crit Care; 2006; 10(3):R97. PubMed ID: 16808853
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
18. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.
McComb MN; Collins CD
Pharmacotherapy; 2014 Jun; 34(6):537-44. PubMed ID: 24390863
[TBL] [Abstract][Full Text] [Related]
20. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]